Scholarlink

<p>Ferroptosis inducers exhibit great potential as anticancer drugs but face two key challenges: (1) non-selective toxicity toward both tumor and immune cells may suppress antitumor immunity; (2) tumor resistance driven by antioxidant defense mechanisms or iron metabolism regulation reduces therapeutic efficacy. To address these issues, herein, a new oxaliplatin(IV) prodrug FAOP by coupling artesunate (ART) and (3-carboxypropionyl) ferrocene (ferrocene fragments) was rationally designed. FAOP could release oxaliplatin (OP), ART and ferrocene fragments, exerting a synergistic anti-cancer effect. Firstly, ferrocene fragments would induce ferroptosis by catalyzing Fenton reaction to generate hydroxyl radicals (·OH), causing lipid peroxidation. Secondly, ART inhibited GPX4 by reducing glutathione (GSH) levels and generating reactive oxygen species (ROS), thereby disrupting the redox balance and further sensitizing cells to ferroptosis. Lastly, OP could induce apoptosis while synergizing with intracellular ROS, resulting in enhanced immunogenic cell death (ICD) and activating both innate and adaptive immunity. The immune effector-activated CD8<sup>+</sup> T cells produced IFN-γ, which inhibited the cystine transport by tumor cells, further impaired GPX4 activation and sensitized ferroptosis. The mutual reinforcement strategy of ICD and ferroptosis mediated by FAOP could overcome the limitations of traditional chemotherapy and reverse immunosuppression caused by ferroptosis inducers, offering a novel idea for designing ferroptosis inducers.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

A new oxaliplatin(IV) prodrug inducing ferroptosis through a triple-pathway mechanism and activating anti-cancer immunity

  • 期刊论文

  • 发表日期：

    2025年6月27日

查看全文
  • Xinda Yang,
  • Nan Huang,
  • Mingyang Li,
  • Xiaoli Zhu,
  • Chunhui Wang,
  • Yue Zhang,
  • Chuansheng Xu,
  • Niantong Yang,
  • Sirui Chen,
  • Yuheng Pan,
  • Bing Shen,
  • Shuo Shi

摘要

Ferroptosis inducers exhibit great potential as anticancer drugs but face two key challenges: (1) non-selective toxicity toward both tumor and immune cells may suppress antitumor immunity; (2) tumor resistance driven by antioxidant defense mechanisms or iron metabolism regulation reduces therapeutic efficacy. To address these issues, herein, a new oxaliplatin(IV) prodrug FAOP by coupling artesunate (ART) and (3-carboxypropionyl) ferrocene (ferrocene fragments) was rationally designed. FAOP could release oxaliplatin (OP), ART and ferrocene fragments, exerting a synergistic anti-cancer effect. Firstly, ferrocene fragments would induce ferroptosis by catalyzing Fenton reaction to generate hydroxyl radicals (·OH), causing lipid peroxidation. Secondly, ART inhibited GPX4 by reducing glutathione (GSH) levels and generating reactive oxygen species (ROS), thereby disrupting the redox balance and further sensitizing cells to ferroptosis. Lastly, OP could induce apoptosis while synergizing with intracellular ROS, resulting in enhanced immunogenic cell death (ICD) and activating both innate and adaptive immunity. The immune effector-activated CD8+ T cells produced IFN-γ, which inhibited the cystine transport by tumor cells, further impaired GPX4 activation and sensitized ferroptosis. The mutual reinforcement strategy of ICD and ferroptosis mediated by FAOP could overcome the limitations of traditional chemotherapy and reverse immunosuppression caused by ferroptosis inducers, offering a novel idea for designing ferroptosis inducers.